Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
DeepSeek Eyes $74 Billion Valuation Ahead of Planned China IPO 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Xi Jinping Calls for People-Centered AI Development at WAIC, Expands Global Cooperation 
SpaceX Aborts Starship Test Flight as Engine Issue Delays Launch 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Trump Administration Launches AI Cybersecurity Partnership to Protect Critical Infrastructure 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Volvo Cars Q2 Profit Falls as Automaker Bets on EX60 EV to Drive Recovery 
NTSB Leads Investigation Into Ryanair Boeing 737 Engine Failure Over Greece 
Lunit, a deep learning-based medical AI company based in South Korea, moved closer to acquiring Volpara Health Technologies Ltd. after the high court in New Zealand issued first-phase approval for the deal.
Lunit is trying to buy Volpara Health, which specializes in making software to save people from cancer. To fulfill its mission of conquering the deadly disease through modern technology, Lunit needs to secure approval from regulators in NZ since the latter is headquartered in the region.
Moving Forward With the Buyout Deal
According to The Korea Economic Daily, the Lunit and Volpara Health agreement is finally moving forward after the high court gave its "go-ahead" for the deal to proceed. With how things are progressing, it was reported that the companies may finalize their acquisition contract by May.
On Thursday, May 14, the South Korean medical AI firm announced it had secured the first approval from the High Court of New Zealand for its plan to buy the NZ-based AI breast cancer diagnostics solutions company.
Moreover, Lunit shared that the acquisition process required by the local court in the region consists of key steps. The first is obtaining the shareholders' approval and the sale vote, and the second is assessing the validity and effectiveness of the meeting's outcome. It was noted that Volpara scheduled a shareholders' meeting for April 12.
Lunit in the American Market
Meanwhile, Lunit's acquisition of Volpara will position the company as a dominant force in the U.S. market for mammography solutions. Once merged, the companies will also improve related artificial intelligence solutions while laying out the foundation for the development of autonomous AI models in the future.
"We are pleased to announce the High Court's approval, a significant step in our remarkable journey. As we approach the final stage where Volpara's shareholders will cast their votes, I would also like to share that our funding for this acquisition is progressing seamlessly, ensuring everything is on track," Lunit's chief executive officer, Brandon Suh, said in a press release. "We are confident that the synergies between Lunit and Volpara will create a powerful force in advancing AI-driven solutions for the benefit of cancer care professionals and patients worldwide."
Photo by: Lunit Press Release
